The effects of Dan Shen Chuanxiong qin injection on serum BNP and cardiac troponin levels in patients with acute coronary syndrome: A Biomechanical Perspective
Abstract
Objective: This study aims to evaluate the clinical efficacy of Dan Shen Chuan xiong qin Injection in combination with conventional interventions for Acute Coronary Syndrome (ACS), emphasizing its biomechanical mechanisms and effects on serum levels of B-type natriuretic peptide (BNP) and cardiac troponin T (cTnT). Methods: This prospective cohort study involved 140 patients suffering from ACS, randomly divided into a control group and a treatment group. The control group received conventional Western pharmacotherapy, while the treatment group was additionally treated with Dan Shen Chuan xiong qin Injection. We measured serum BNP and cardiac troponin levels and analyzed their biomechanical relevance to cardiac function and hemodynamics on the 1st, 2nd, and 5th days post-treatment. Results: After treatment, particularly on the 5th day, the BNP levels in the treatment group receiving Dan Shen Chuan xiong qin Injection were significantly lower than those in the control group (p < 0.05). Both groups exhibited a downward trend in BNP levels on days 1, 2, and 5 (p < 0.001). Regarding troponin levels, the treatment group showed lower troponin levels on all days compared to the control group (p < 0.05), with statistically significant differences noted (p < 0.05). Biomechanical Analysis: The reduction in BNP and troponin levels suggests an improvement in cardiac function and hemodynamics, potentially indicating enhanced myocardial performance and reduced cardiac stress. The biomechanical implications of these biomarkers highlight their role in assessing cardiac workload and injury, reinforcing the cardioprotective effects of Dan Shen Chuanxiong Injection. Conclusion: The treatment group receiving Dan Shen Chuanxiong Injection demonstrated superior outcomes in clinical symptom relief, improvement in cardiac function, and reduction in biomarker levels compared to the control group. These findings indicate that Dan Shen Chuan xiong qin Injection possesses significant cardioprotective effects, reducing the risk of cardiac injury through biomechanical mechanisms. When used alongside conventional therapy, DSCXQ Injection shows potential for improving critical biomarkers related to ACS. This study provides valuable evidence for integrating traditional Chinese medicine with conventional Western approaches in managing ACS, emphasizing the importance of biomechanical analysis in understanding therapeutic effects.
References
1. Ni Zheng, Peng Weihong. Efficacy of Dabigatran Etexilate in the Treatment of Atrial Fibrillation Complicated by Acute Coronary Syndrome and Its Impact on Patient Prognosis[J]. Medical Information, 2024, 37(17): 117-119+123.
2. Dai Chengye, Deng Yifan, He Shenghu, et al. The Predictive Value of Monocyte Count/High-Density Lipoprotein Cholesterol and Thyroid-Stimulating Hormone on Acute Coronary Syndrome in Postmenopausal Women and Their Correlation with Coronary Artery Lesions[J]. Chinese General Practice, 2024, 27(33): 4132-4138.
3. Chen Yingtao, Fang Kangkang, Zhang Jinao, et al. Coronary CT Angiography Image Segmentation Network Based on Multiscale Spatial Features[J/OL]. Computer Applications,1-12[2024-10-28]. http://kns.cnki.net/kcms/detail/51.1307.TP.20241018.1444.008.html.
4. Geng Lianfang, Yao Dianzhong, Li Zhi, et al. Clinical Study on the Treatment of Acute Exacerbation of Chronic Respiratory Failure with Dan Shen and Chuanxiong Zhi Injection Combined with Nicorandil[J]. Modern Pharmaceuticals and Clinics, 2024, 39(07): 1797-1801.
5. Luo Xin, Luo Ying. Progress in Clinical Application Research of Dan Shen and Chuanxiong Zhi Injection[J]. Journal of Feet and Health, 2018, 27(08): 166-167. doi: 10.19589/j.cnki.issn1004-6569.2018.08.166.
6. Zhang Xia, Zhao Yanfang. Progress in Research of Traditional Chinese Medicine for Preventing and Treating Myocardial Injury in Patients Undergoing PCI for Coronary Heart Disease[J]. Journal of Traditional Chinese Medicine, 2021, 33(06): 1213-1216. doi: 10.16448/j.cjtcm.2021.0649.
7. Gu Lijun. Evaluation of the Value of Dan Shen and Chuanxiong Zhi Injection in Treating Angina Pectoris Due to Coronary Heart Disease[J]. Chinese Prescription Medicines, 2015, 13(12): 80-81.
8. Sun Hongzhou, Wang Na. Clinical Study on Leflutrozole Combined with Dan Shen and Chuanxiong Zhi Injection for Chronic Refractory Heart Failure[J]. Journal of Laboratory Medicine and Clinical Studies, 2023, 20(24): 3688-3692.
9. Zhang Hongwei, Xie Yanming, Gao Yang, et al. Clinical Characteristics of Dan Shen and Chuanxiong Zhi Injection in Real-World Settings and Characteristics of Combined Medication[J]. Chinese Journal of Traditional Chinese Medicine, 2021, 39(06): 55-60. doi: 10.13193/j.issn.1673-7717.2021.06.010.
10. Wang Jiaqin. Study on the Hemorheological Characteristics of Blood Stasis Syndrome Patients After Acute Coronary Syndrome Interventional Procedures[D]. Beijing University of Chinese Medicine, 2012.
11. Peipei Z, Lin Z, Yingying S, et al.Neuroprotective Effects of Danshen Chuanxiongqin Injection Against Ischemic Stroke: Metabolomic Insights by UHPLC-Q-Orbitrap HRMS Analysis [J].Frontiers in Molecular Biosciences,2021,8630291-630291.
12. Bo L, Fei-Hu Z, Ling F, et al.Chinese Herbal Medicine Dingji Fumai Decoction for Ventricular Premature Contraction: A Real-World Trial.[J].BioMed research international,2020,20205358467.
13. Zeng Guobin, Yang Wei. The Value of Plasma N-terminal Pro-B-Type Natriuretic Peptide Levels in Judging Recent Prognosis in ACS Patients[J]. Shandong Medical Journal, 2013, 53(05): 72-73.
14. Wu Guoping, Huang Xiaohui, Yao Zhen. Effects of Danshen Chuanxiongqin Injection on High-sensitivity C-reactive Protein and Cardiac Function in Patients with Acute Coronary Syndrome[J]. Journal of Hainan Medical University, 209, 15(08):858-860. doi: 10.13210/j.cnki.jhmu2009.08.004.
15. Gao Hui, Pang Xinmei, Wang Hao, et al. Clinical Research Progress on Biomarkers for Acute Heart Failure[J]. Chinese Journal of Health Preservation and Medicine, 2024, 42(12): 84-87.
16. Arzani, A., Wang, JX., Sacks, M.S. et al. Machine Learning for Cardiovascular Biomechanics Modeling: Challenges and Beyond. Ann Biomed Eng 50, 615–627 (2022). https://doi.org/10.1007/s10439-022-02967-4
17. Salman HE, Yalcin HC. Computational Modeling of Blood Flow Hemodynamics for Biomechanical Investigation of Cardiac Development and Disease. Journal of Cardiovascular Development and Disease. 2021; 8(2):14. https://doi.org/10.3390/jcdd8020014
18. Rostam-Alilou, A.A., Jarrah, H.R., Zolfagharian, A. et al. Fluid–structure interaction (FSI) simulation for studying the impact of atherosclerosis on hemodynamics, arterial tissue remodeling, and initiation risk of intracranial aneurysms. Biomech Model Mechanobiol 21, 1393–1406 (2022). https://doi.org/10.1007/s10237-022-01597-y
19. Fandaros, M., Kwok, C., Wolf, Z. et al. Patient-Specific Numerical Simulations of Coronary Artery Hemodynamics and Biomechanics: A Pathway to Clinical Use. Cardiovasc Eng Tech 15, 503–521 (2024). https://doi.org/10.1007/s13239-024-00731-4
20. Chen J, Wei X, Zhang Q, et al. The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms. Acta Pharm Sin B. 2023;13(5):1919-1955. doi: 10.1016/j.apsb.2023.02.005
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
